In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector for part 2 of our conversation with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• The story behind Recipharm’s decision to divest Cobra Biologics that led Thomas to become owner
• How ‘big faith’ and the gene therapy revolution changed the fortunes of the loss-making biologics CDMO
• After the third exit, why did he choose ‘passion rather than pension’? To fuel his love for creating things and building companies
• Flerie’s mission and its patient-centric investment strategy in life sciences.
• The story behind Thomas’ signature bowtie look…

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries.

He was also the founder of Flerie Invest AB in 2011, where he is currently the executive chairman. Thomas is presently chairman of the board and a member of the board of several life science companies. He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with part 1 of our episode with Thomas Eldered, Executive Chairman at Flerie.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Thomas, covering:

• Where his entrepreneurial spark originated, and how they created a CMO (before that was even a thing) after several failed plans
• How did the timing of his first exit and having ‘cash during the crash’ fuel M&A to grow Recipharm into an international powerhouse?
• Why did he decide to go public? No one else in Sweden or in the CDMO space was getting an IPO
• A lifetime with Lars (his business partner) and the benefit of a partnership with aligned common interest
• Why he decided to sell Recipharm after 26 years and why leaving the company was the most difficult mental decision

Thomas Eldered was co-founder of Recipharm AB in 1995, where he served as CEO from 2008 to 2021, growing Recipharm from a local Swedish pharmaceutical contract manufacturer to an international CDMO with more than 9000 employees in 10 countries. He also founded Flerie Invest AB in 2011, where he is currently Executive Chairman. Thomas is currently chairman of the board and a member of the board of several life science companies.

He holds a Master of Science in Industrial Engineering and Management from Linköping University.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Dan Mamelak, Founder & President at Custom Biologics.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dan, covering:

• How reading The Billion-dollar Molecule book inspired him to explore a pathway into cutting-edge drug development
• The founding story of his company and some timeless advice not to burn bridges
• How the Canadian conveyor belt of intelligent, talented young science graduates has helped fuel the company’s growth
• Why being privately owned has contributed to the company’s unique culture

Dan is responsible for the company's strategic direction. From the outset of his career, Dan recognized the need for solid bioanalytical expertise to support the drug discovery programs of both developing and established biopharmaceutical companies.

In 2004, Dan established Custom Biologics, a large-molecule bioanalytical CRO that designs and validates assays to measure the potency of biotherapeutic drugs, including therapeutic monoclonal antibodies and genetic therapies. Recently, the Genomics division of Custom Biologics has developed novel isothermal nucleic acid molecular diagnostic tests to rapidly identify human and food-borne pathogens.

Before founding Custom Biologics, Dan was a Senior Scientist at Affinium Pharmaceuticals, an established company that accelerates the development of small molecules into new medicines. Dan holds a Ph.D. in Biochemistry from the University of Toronto.

Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.